Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.32 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26624063 | 1.00 | AKR1C4 (0.58) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL2948165 | 1.00 | AKR1C4 (0.58) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL2420552 | 1.00 | AKR1C4 (0.58) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| Acetic Acid SCHEMBL57726 | 0.92 | AKR1C4 (0.62) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL26626337 | 0.81 | AKR1C4 (0.71) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL19604584 | 0.81 | AKR1C4 (0.71) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL19604624 | 0.81 | AKR1C4 (0.71) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL14373673 | 0.81 | AKR1C4 (0.71) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL21383060 | 0.80 | AKR1C4 (0.56) | AKR1C4AKR1C3AKR1C2HTTPTGER2 | |
| SCHEMBL9842994 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| WO-2008116339-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| US-4496767-A | REARRANGEMENT, ESTERIFICATION AND REDUCTION OF A FURAN-CARBINOL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113460-A1 | Organic Compounds | CYP2B6, CYP2A6, CYP2A13 | AKR1C4 291/4885AKR1C3 330/4885AKR1C2 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.